Company: SION
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0002036042-25-000005
Chunk: 217

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 217
---
&D acquisition—— —— —— —— 1,414,4452 8,637 8,639 Exercise of common stock options—— —— —— —— 71,2641 140 — — 141 Vesting of restricted common stock awards—— —— —— —— 186,191— — — — — Stock-based compensation expense—— —— —— —— —— 3,708 — — 3,708 Unrealized gain on marketable debt securities—— —— —— —— —— — 368 — 368 Net loss—— —— —— —— —— — — (61,688)(61,688)Balance at December 31, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 4,722,763$5 $17,000 $368 $(181,086)$(163,713)

The accompanying notes are an integral part of these consolidated financial statements. 

F-5

SIONNA THERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands) 

Year Ended December 31,20242023Cash flows from operating activities:  Net loss$(61,688)$(47,263)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash expense related to IPR&D acquisition8,639 — Stock-based compensation expense3,708 2,259 Non-cash operating lease expense1,962 2,184 Amortization of discount on marketable securities(3,001)(679)Depreciation expense668 583 Changes in operating assets and liabilities:Prepaid expenses and other current assets(2,760)333 Accounts payable467 162 Accrued expenses1,080 (1,106)Operating lease liabilities(1,897)(172)Other assets35 — Net cash used in operating activities(52,787)(43,699)Cash flows from investing activities:Purchases of property and equipment(27)(1,116)Purchases of marketable securities(182,841)(23,532)Maturities of marketable securities55,955 52,000 Net cash (used in) provided by